The discovery of genomic and epigenetic alterations in individual cancers has led to a plethora of precision medicine innovations and therapeutic successes in oncology. Accordingly, cancer treatments have migrated away from the “one size fits all” approach. However, even as precision medicine is becoming more multi-disciplinary, progress is still hindered by insufficient collaboration between basic researchers, drug development programs, and physician scientists with broad expertise across cancer biology, genomics and other relevant fields.
This conference program will cover topics such as novel genomic insights, therapeutically promising mechanisms and cancer drug targets, recent translational breakthroughs, and the incorporation of new diagnostic tools as companions to new precision treatments. The program will emphasize leading-edge advances in “reverse translation” technologies, such as liquid biopsies and single cell genomics, in addition to innovative, first-in-class approaches to novel therapeutics. Ultimately, the goal of the conference is to forge new collaborations across scientific and clinical boundaries, to advance the next generation of precision medicines against cancer.
Come join Mission Bio at our virtual booth as we partner with Keystone where you can learn about implementing single-cell analysis in advanced therapy development, download resources and chat live with our team.
